Examkin

Soru

Zorluk: ZorHematology and Oncology

Match each clinical presentation of a chemotherapy-induced adverse effect to the specific antineoplastic agent responsible for the toxicity.

  • A 28-year-old man receiving bleomycin, etoposide, and cisplatin for testicular cancer develops a dry cough and progressive dyspnea; pulmonary function tests show a restrictive pattern.Bleomycin
  • A 48-year-old woman receiving rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone for non-Hodgkin lymphoma presents with suprapubic pain and gross hematuria.Cyclophosphamide
  • A 62-year-old man receiving bleomycin, etoposide, and cisplatin for advanced testicular cancer complains of persistent bilateral tinnitus and progressive sensorineural hearing loss.Cisplatin
  • A 55-year-old woman receiving doxorubicin and cyclophosphamide for breast cancer develops new-onset orthopnea, bilateral basilar crackles, and a reduced left ventricular ejection fraction.Doxorubicin
  • A 60-year-old man receiving rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone for diffuse large B-cell lymphoma reports a subacute 'pins and needles' sensation in his distal extremities and absent ankle reflexes.Vincristine

Cevap

The correct matches align the clinical toxicity to its specific causative agent: Bleomycin causes pulmonary fibrosis; Cyclophosphamide causes hemorrhagic cystitis; Cisplatin causes ototoxicity; Doxorubicin causes dilated cardiomyopathy; and Vincristine causes peripheral neuropathy.
Each clinical scenario describes a classic dose-limiting toxicity that corresponds to exactly one agent in the patient's regimen. Bleomycin causes pulmonary fibrosis; Cyclophosphamide causes hemorrhagic cystitis; Cisplatin causes ototoxicity; Doxorubicin causes dilated cardiomyopathy; and Vincristine causes peripheral neuropathy.

Adım Adım Çözüm

1
Analyze the first vignette describing restrictive lung disease in a patient on BEP therapy.
The primary symptom is pulmonary fibrosis.
Identifying the specific organ toxicity allows isolation of the responsible drug from the combination regimen.
2
Match pulmonary fibrosis to its causative agent in the BEP regimen.
Bleomycin is the correct match.
Bleomycin is classically associated with dose-dependent pulmonary toxicity.
3
Analyze the second vignette describing gross hematuria in a patient on R-CHOP therapy.
The presentation represents hemorrhagic cystitis.
This is a classic urologic emergency associated with specific alkylating agents.
4
Match hemorrhagic cystitis to its causative agent.
Cyclophosphamide is the correct match.
Acrolein, a cyclophosphamide metabolite, is highly toxic to the bladder epithelium.
5
Analyze the third vignette describing tinnitus and hearing loss in a patient on BEP therapy.
The symptom is ototoxicity.
Hearing loss is a highly specific neurological toxicity that must be recognized.
6
Match ototoxicity to its causative agent.
Cisplatin is the correct match.
Platinum analogues, especially cisplatin, are heavily ototoxic and nephrotoxic.
7
Analyze the fourth vignette describing heart failure (reduced ejection fraction) in a patient on AC therapy.
The symptom is dilated cardiomyopathy.
Cardiotoxicity is a dose-limiting side effect for certain key oncology drugs.
8
Match dilated cardiomyopathy to its causative agent.
Doxorubicin is the correct match.
Anthracyclines like doxorubicin cause cumulative myocardial free-radical damage.
9
Analyze the fifth vignette describing absent ankle reflexes and paresthesias in a patient on R-CHOP therapy.
The symptom is peripheral neuropathy.
Areflexia and a 'pins and needles' sensation indicate peripheral nerve damage.
10
Match peripheral neuropathy to its causative agent.
Vincristine is the correct match.
Vinca alkaloids disrupt microtubules, uniquely causing peripheral neuropathy rather than the severe myelosuppression seen with other agents.

Anahtar Kavram

Major chemotherapeutic agents have distinct, highly tested dose-limiting toxicities that must be recognized when patients on combination regimens present with new symptoms.
Bu soruyu puanla

Konular

Hematology and Oncology

Bu konudan daha fazla soru